Head-to-head · WeighScore
Rewinding RX vs Tablet Health
The verdict
Rewinding RX takes it — 59.5/100 to 47.6/100.
Rewinding RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rewinding RX is a longevity-focused telehealth platform that frames compounded GLP-1 therapy within a broader biological-age-reversal program alongside NAD+ and functional-medicine protocols.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Rewinding RX | Tablet Health |
|---|---|---|
| WeighScore | 59.5/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #340 | #495 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #340 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer — uncommon transparency
- MD-only physician network ('never a physician assistant or nurse')
- All-50-state coverage with physician state-licensing matching
- Corporate entity disclosed (Rewinding RX Ltd.)
Where it loses points
- Pricing not shown — fully gated behind sign-up
- Pharmacy partner not named (only generic 503A/503B references)
- Medical director / clinical leadership not disclosed
- Governing law, arbitration venue, and corporate address not disclosed
- Tirzepatide not listed on the homepage (semaglutide only confirmed)
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.